E Jason Abel1, Brian J Linder2, Tyler M Bauman3, Rebecca M Bauer4, R Houston Thompson2, Prabin Thapa5, Octavia N Devon3, Robert F Tarrell5, Igor Frank2, David F Jarrard3, Tracy M Downs3, Stephen A Boorjian2. 1. Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Electronic address: abel@urology.wisc.edu. 2. Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN, USA. 3. Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 4. Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 5. Department of Health Science Research, Mayo Medical School and Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND: While perioperative blood transfusion (BT) has been associated with adverse outcomes in multiple malignancies, the importance of BT timing has not been established. OBJECTIVE: The objective of this study was to evaluate whether intraoperative BT is associated with worse cancer outcomes in bladder cancer patients treated with radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: Outcomes from two independent cohorts of consecutive patients with bladder cancer treated with RC were analyzed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Recurrence-free survival, cancer-specific survival (CSS), and overall survival were estimated and multivariate analyses were performed to evaluate the association of BT timing with cancer outcomes. RESULTS AND LIMITATIONS: In the primary cohort of 360 patients, 241 (67%) received perioperative BT, including 162 intraoperatively and 79 postoperatively. Five-year CSS was 44% among patients who received an intraoperative BT versus 64% for patients who received postoperative BT (p=0.0005). After multivariate analysis, intraoperative BT was associated with an increased risk of cancer mortality (hazard ratio [HR]: 1.93; p=0.02), while receipt of postoperative BT was not (p=0.60). In the validation cohort of 1770 patients, 1100 (62%) received perioperative BT with a median postoperative follow-up of 11 yr (interquartile range: 8.0-15.7). Five-year RFS (p<0.001) and CSS (p<0.001) were significantly worse among patients who received an intraoperative BT. Intraoperative BT was independently associated with recurrence (HR: 1.45; p=0.001), cancer-specific mortality (HR: 1.55; p=0.0001), and all-cause mortality (HR: 1.40; p<0.0001). Postoperative BT was not associated with risk of disease recurrence or cancer death. CONCLUSIONS: Intraoperative BT is associated with increased risk of bladder cancer recurrence and mortality. PATIENT SUMMARY: In this study, the effects of blood transfusion on bladder cancer surgery outcomes were evaluated. Intraoperative blood transfusion, but not postoperative transfusion, was associated with higher rates of recurrence and cancer-specific mortality.
BACKGROUND: While perioperative blood transfusion (BT) has been associated with adverse outcomes in multiple malignancies, the importance of BT timing has not been established. OBJECTIVE: The objective of this study was to evaluate whether intraoperative BT is associated with worse cancer outcomes in bladder cancerpatients treated with radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: Outcomes from two independent cohorts of consecutive patients with bladder cancer treated with RC were analyzed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Recurrence-free survival, cancer-specific survival (CSS), and overall survival were estimated and multivariate analyses were performed to evaluate the association of BT timing with cancer outcomes. RESULTS AND LIMITATIONS: In the primary cohort of 360 patients, 241 (67%) received perioperative BT, including 162 intraoperatively and 79 postoperatively. Five-year CSS was 44% among patients who received an intraoperative BT versus 64% for patients who received postoperative BT (p=0.0005). After multivariate analysis, intraoperative BT was associated with an increased risk of cancer mortality (hazard ratio [HR]: 1.93; p=0.02), while receipt of postoperative BT was not (p=0.60). In the validation cohort of 1770 patients, 1100 (62%) received perioperative BT with a median postoperative follow-up of 11 yr (interquartile range: 8.0-15.7). Five-year RFS (p<0.001) and CSS (p<0.001) were significantly worse among patients who received an intraoperative BT. Intraoperative BT was independently associated with recurrence (HR: 1.45; p=0.001), cancer-specific mortality (HR: 1.55; p=0.0001), and all-cause mortality (HR: 1.40; p<0.0001). Postoperative BT was not associated with risk of disease recurrence or cancer death. CONCLUSIONS: Intraoperative BT is associated with increased risk of bladder cancer recurrence and mortality. PATIENT SUMMARY: In this study, the effects of blood transfusion on bladder cancer surgery outcomes were evaluated. Intraoperative blood transfusion, but not postoperative transfusion, was associated with higher rates of recurrence and cancer-specific mortality.
Authors: D Robert Siemens; Melanie T Jaeger; Xuejiao Wei; Francisco Vera-Badillo; Christopher M Booth Journal: World J Urol Date: 2017-02-17 Impact factor: 4.226
Authors: Juan P Cata; Cristina Gutierrez; Reza J Mehran; David Rice; Joseph Nates; Lei Feng; Andrea Rodriguez-Restrepo; Fernando Martinez; Gabriel Mena; Vijaya Gottumukkala Journal: Cancer Cell Microenviron Date: 2016
Authors: Aditya Bagrodia; Samuel Kaffenberger; Andrew Winer; Katie Murray; Michael Vacchio; Junting Zheng; Irina Ostrovnaya; Bernard H Bochner; Guido Dalbagni; Eugene K Cha; Jonathan A Coleman Journal: World J Urol Date: 2018-01-17 Impact factor: 4.226
Authors: Jens Mani; Stefan Vallo; Maximilian P Brandt; Kilian M Gust; Claudia Bartsch; Johannes Daechert; Igor Tsaur; Georg Bartsch; Axel Haferkamp Journal: Patient Prefer Adherence Date: 2016-10-28 Impact factor: 2.711